| 摘要: |
| [摘要]目的：探讨双歧杆菌四联活菌联合孟鲁司特钠对过敏性紫癜患儿炎性因子和免疫功能的影响。方法：选取2016年6月到2017年6月在我院接受治疗的过敏性紫癜患儿120例，根据随机数表法分为观察组和常规治疗组各60例，常规治疗组采用常规方法治疗，观察组在常规治疗的基础上加用双歧杆菌四联活菌联合孟鲁司特钠进行治疗，两组均连续治疗1个月，观察两组患儿的临床疗效、不良反应发生率和复发率，比较两组患儿治疗前后的炎症因子、T淋巴细胞亚群及免疫球蛋白水平。结果：观察组的总有效率为95.00%，明显高于常规治疗组的83.33%（P<0.05）；在治疗过程中，两组患儿均未出现明显的不良反应；观察组的复发率为8.33%，低于常规治疗组的21.67%（P<0.05）。治疗后观察组的IL-9、IL-17、IL-23、TNF-α水平分别为（21.89±6.97）pg/mL、（19.49±3.48）pg/mL、（20.68±3.97）pg/mL、（110.26±21.26）ng/L，均低于常规治疗组的（29.46±7.83）pg/mL、（24.16±4.26）pg/mL、（27.56±4.61）pg/mL、（150.37±26.48）ng/L（P<0.05）；治疗后观察组的IFN-γ水平为（23.68±2.57）pg/mL，高于常规治疗组的（19.52±2.04）pg/mL，IL-4水平为（13.29±2.28）pg/mL，低于常规治疗组的（16.19±2.36）pg/mL（P<0.05）；治疗后观察组的CD4+、CD4+/CD8+分别为（36.52±3.93）%、（1.47±0.16），高于常规治疗组的（32.73±4.22）%、（1.21±0.11），CD8+为（24.83±2.41）%，低于常规治疗组的（27.02±2.45）%（P<0.05）；治疗后观察组IgA水平为（1.42±0.64）g/L，低于常规治疗组的（1.95±0.71）g/L（P<0.05）。结论：双歧杆菌四联活菌联合孟鲁司特钠应用于过敏性紫癜患儿可降低机体炎症反应，促进Th1/ Th2细胞平衡，改善机体免疫功能，降低复发率，具有较好的临床疗效，且安全性较好。 |
| 关键词: 过敏性紫癜 双歧杆菌四联活菌片 孟鲁司特钠 炎性因子 免疫功能 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2019.04.009 |
|
| 基金项目:2014年度山东省医药卫生科技发展计划项目，编号2014WS0052。 |
|
| Bifidobacterium Tetra Viable Tablets Combined with Montelukast Sodium on Inflammatory Factors and Immune Function in Children with Henoch-Schönlein Purpura |
| Sang Miao, Liu Yapan |
| (Women's and Children's Hospital, the Second People's Hospital of Dongying, Shandong Dongying 257335, China) |
| Abstract: |
| [Abstract] Objective: To probe into the effects of Bifidobacterium tetra viable tablets combined with montelukast sodium on inflammatory factors and immune function in children with Henoch-Schönlein purpura. Methods: Totally 120 children with Henoch-Schönlein purpura admitted into our hospital from Jun. 2016 to Jun. 2017 were extracted to be divided into the observation group and the control group via the random number table, with 60 cases in each group. The control group was treated by conventional treatment methods, and the observation group received Bifidobacterium tetra viable tablets combined with montelukast sodium on the basis of conventional treatment. Two groups were treated continuously for 1 month. The clinical efficacy, adverse drug reactions and recurrence of two groups were observed. The inflammatory factors, T lymphocyte subsets and immunoglobulin levels were compared between two groups before and after treatment. Results: The total effective rate of the observation group was 95.00%, significantly higher than that of the control group 83.33% (P<0.05). During the treatment, no obvious adverse reactions were found in two groups. The recurrence rate of the observation group was 8.33%, lower than that of the control group 21.67% (P<0.05). After treatment, the levels of IL-9, IL-17, IL-23 and TNF-α in the observation group were (21.89±6.97) pg/mL, (19.49±3.48) pg/mL, (20.68±3.97) pg/mL and (110.26±21.26) ng/L, lower than those in the control group (29.46±7.83) pg/mL, (24.16±4.26) pg/mL, (27.56±4.61) pg/mL and (150.37±26.48) ng/L (P<0.05). After treatment, the level of IFN-γ in the observation group was (23.68±2.57) pg/mL, higher than that in the control group (19.52±2.04) pg/mL, and the level of IL-4 was (13.29±2.28) pg/mL, lower than that in the control group (16.19±2.36) pg/mL (P<0.05). After treatment, the CD4+ and CD4+/CD8+ in the observation group were respectively (36.52±3.93)% and 1.47±0.16, higher than those of the control group (32.73±4.22)% and 1.21±0.11, and the CD8+ of the observation group was (24.83±2.41)%, lower than that of the control group (27.02±2.45)% (P<0.05). The level of IgA in the observation group was (1.42±0.64) g/L after treatment, lower than that in the control group (1.95±0.71) g/L (P<0.05). Conclusion: Bifidobacterium tetra viable tablets combined with montelukast sodium can reduce the inflammatory response in children with Henoch-Schönlein purpura, promote the balance of Th1/Th2 cells, improve the immune function of the body, reduce the recurrence rate, and it has more significant clinical efficacy and better safety. |
| Key words: Henoch-Schönlein purpura Bifidobacterium tetra viable tablets montelukast sodium inflammatory factors immune function |
